Kennett Square, PA, United States of America

Argyrios George Arvanitis

USPTO Granted Patents = 24 (Patent Applications = 3)

CIPO Patents = 6

EPO Patents = 14 (Patent Applications = 12)

Average Co-Inventor Count = 3.8

ph-index = 12

Forward Citations = 954(Granted Patents)

Company Filing History:

Bristol-myers Squibb Compnay

patents

4 out of 147

Incyte Holdings Corporation

patents

4. 2 out of 234

Bristol-myers Squibb Pharma Company

patents

5. 1 out of 106

Dupont Pharmaceuticals Company

The Dupont Merck Pharmaceutical Company

patents

8. 1 out of 10

Bristol-myers Squibb Pharma Corporation

patents

where one patent can have more than one assignee

Years Active: 1995-2019

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10463667 - Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2019-11-05),

2. 9512161 - Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2016-12-06),

3. 9359358 - Cyclohexyl azetidine derivatives as JAK inhibitors (2016-06-07),

4. 9334274 - N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors (2016-05-10),

5. 8889697 - Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2014-11-18),

6. 8841318 - Substituted heterocycles as janus kinase inhibitors (2014-09-23),

7. 8835423 - Azepine inhibitors of janus kinases (2014-09-16),

8. 8748401 - Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2014-06-10),

9. 8716303 - N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors (2014-05-06),

10. 8563541 - Azepine inhibitors of Janus kinases (2013-10-22),

11. 8513270 - Substituted heterocycles as Janus kinase inhibitors (2013-08-20),

12. 8486902 - Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2013-07-16),

13. 8415362 - Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors (2013-04-09),

14. 7319100 - Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands (2008-01-15),

15. 7205306 - Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands (2007-04-17),

Title: Argyrios George Arvanitis: Innovator in Medicinal Chemistry

Introduction

Argyrios George Arvanitis is an esteemed inventor based in Kennett Square, PA, whose contributions to medicinal chemistry are reflected in his impressive portfolio of 24 patents. His work primarily focuses on the development of pharmacologically active compounds that play crucial roles in treating various health conditions.

Latest Patents

Among his most recent innovations is his patented work on "Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile." This invention reveals active metabolites that modulate the activity of Janus kinases, showing potential for treating diseases related to immune functions, skin disorders, myeloid proliferative disorders, cancer, and more. Additionally, he holds a patent for "Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile," which presents various derivatives of the aforementioned compound, expanding his contributions to the field further.

Career Highlights

Argyrios George Arvanitis has had a distinguished career with notable affiliations with prestigious companies, including Incyte Corporation and Bristol-Myers Squibb Company. His roles at these organizations have allowed him to work on significant projects that bridge the gap between innovative research and practical medicinal applications.

Collaborations

Throughout his career, Arvanitis has collaborated with esteemed professionals in his field, including James David Rodgers and Stacey Shepard. These collaborations have not only enriched his research but also contributed to breakthroughs in medicinal chemistry and therapeutic developments.

Conclusion

Argyrios George Arvanitis continues to push the boundaries of innovation in medicinal chemistry with his extensive patent portfolio and collaborative efforts. His work stands as a testament to the power of invention in addressing complex health challenges, showcasing the vital role of scientists and inventors in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.